VetMedGuide

Vet Med Guide

Pharmaceuticals2026-05-14 · 9 min read

Laverdia for Dogs: At-Home Oral Lymphoma Treatment and Chemo-Handling Safety

Laverdia (verdinexor) is the first FDA fully approved oral treatment for canine lymphoma.

Ran Chen
Ran Chen
Founder, VetMedGuide. Life-sciences operator and 10× global market-access lead.
Published

In January 2026 the FDA granted full approval to Laverdia (verdinexor tablets) for the treatment of lymphoma in dogs — making it the first oral at-home treatment ever fully approved for canine lymphoma. Laverdia had been available under conditional approval since January 2021. After four annual renewals and a pivotal field study of 160 dogs, the sponsor (Anivive Lifesciences) demonstrated substantial evidence of effectiveness, and the drug transitioned to full approval.

This article covers how Laverdia works, how it is dosed and administered at home, what side effects to expect, the safety precautions owners must follow when handling a chemotherapy drug in their household, and how Laverdia fits into the broader landscape of canine lymphoma treatment alongside injectable CHOP chemotherapy and Tanovea (rabacfosadine).

Quick answer

Laverdia is a selective inhibitor of nuclear export (SINE). It blocks exportin 1 (XPO1), a transport protein that shuttles tumor-suppressor proteins (TSPs) out of the cell nucleus. In lymphoma cells, TSPs like p53 are frequently over-exported, allowing the cancer to grow unchecked. By blocking XPO1, Laverdia traps TSPs inside the nucleus, where they resume their tumor-suppressing function and the cancer cell dies.

The labeled dosing schedule is twice weekly — for example, Monday and Thursday, with at least 72 hours between doses. The starting dose is 1.25 mg/kg orally. If tolerated after two weeks, the dose increases to 1.5 mg/kg twice weekly. Tablets come in 2.5 mg, 10 mg, and 50 mg strengths and must be given with food. Laverdia is available only by prescription from a licensed veterinarian.

What the pivotal field study showed

The effectiveness data supporting full approval came from a multi-center, prospective, randomized, masked, controlled field study of 160 dogs with lymphoma and at least one measurable peripheral lymph node. The study enrolled dogs with B-cell lymphoma (approximately 80% of dogs) and T-cell lymphoma (approximately 18%), and included both treatment-naive dogs (60%) and dogs that had relapsed after prior chemotherapy (40%).

The primary endpoint was time to disease progression. Dogs treated with Laverdia experienced a median time to progression of 37 days, compared to 23 days for the placebo control group — a statistically significant difference (P = 0.011).

This is not a comparison to CHOP chemotherapy, which achieves complete remission rates of 80–90% with median survival times of 12–14 months for B-cell lymphoma. Laverdia fills a different niche: it is an oral option for dogs whose owners cannot or choose not to pursue injectable chemotherapy, or for dogs that have relapsed after prior treatment.

Dosing and administration

Laverdia is administered at home by the owner, which is unusual for a chemotherapy drug. The label instructions are specific:

  1. Feed the dog immediately before giving Laverdia. Food improves absorption.
  2. Wear protective disposable chemotherapy-resistant gloves when handling the tablets, the dog's food and water bowls, and when cleaning up after the dog.
  3. Starting dose: 1.25 mg/kg orally, twice per week (e.g., Monday and Thursday), with at least 72 hours between doses.
  4. After two weeks, if the dog tolerates the medication, increase to 1.5 mg/kg twice per week with at least 72 hours between doses.
  5. Dose reductions of 0.25 mg/kg are allowed to a minimum of 1 mg/kg twice weekly, or treatment may be interrupted for adverse reactions.

Dose tablets should not be broken or crushed. If a dose is vomited, contact the prescribing veterinarian for guidance — do not re-dose without instruction. The dosing schedule above reflects the FDA-approved label; the prescribing veterinarian will determine the appropriate dose for each dog and may adjust based on response and tolerance.

Owner safety: this is a chemotherapy drug

Laverdia is not a supplement or a pain medication. It is a cytotoxic anticancer drug, and the handling precautions are serious. The label and client information sheet are explicit:

  • Pregnant women, women who may become pregnant, and nursing women must not handle Laverdia or come into contact with the feces, urine, vomit, or saliva of treated dogs. Laverdia may affect female and male fertility.
  • Children must not touch Laverdia or the feces, urine, vomit, or saliva of treated dogs.
  • Wear chemotherapy-resistant gloves (not standard kitchen gloves) when handling the tablets, the dog's food and water bowls, and when cleaning up any waste. The precaution window extends for 3 days after the last dose.
  • If Laverdia is accidentally ingested by a person, or if there is significant unprotected contact with the dog's waste during treatment, seek medical advice immediately.
  • Do not use in dogs that are pregnant, nursing puppies, or intended for breeding.

These precautions are more intensive than what most pet owners expect for a medication given at home. Before starting Laverdia, the veterinarian should walk the owner through the client information sheet, confirm that the household can comply with the safety requirements, and discuss what to do if a dose is missed, vomited, or if another household member (including a child) accidentally handles the medication.

Side effects

The most commonly reported adverse reactions in the field study and safety trials include:

  • GI signs — decreased appetite, vomiting, diarrhea, and weight loss. The label advises stopping Laverdia and contacting a veterinarian if the dog refuses food for more than one day or has repeated vomiting or diarrhea.
  • Lethargy — reported as a reason to contact the veterinarian between scheduled visits.
  • Hematologic changes — decreases in white blood cell count, red blood cell count, and platelets. These are monitored through regular blood work.
  • Blood chemistry changes — elevated liver enzymes, elevated kidney values, and electrolyte shifts. Monitoring blood chemistry at regular intervals is part of the treatment protocol.

Monitoring is typically every 1–2 weeks initially, decreasing in frequency once the veterinarian is confident the dog is tolerating the medication. If adverse reactions occur, the dose can be reduced by 0.25 mg/kg increments or treatment can be paused.

How Laverdia compares to other lymphoma treatments

Factor Laverdia (verdinexor) CHOP chemotherapy Tanovea (rabacfosadine)
Route Oral, at home Injectable, in clinic Injectable, in clinic
Frequency Twice weekly Multi-drug rotation over ~6 months Every 3 weeks for up to 5 doses
Mechanism Nuclear export inhibitor (XPO1) Multi-agent cytotoxic cocktail DNA synthesis inhibitor
Remission rates Lower than CHOP; time to progression 37 days in field study 80–90% complete remission (B-cell) Response rate approximately 77% in label study
Owner burden Home administration with chemo-safe handling Frequent clinic visits Clinic visits every 3 weeks
Best fit Owners who decline or cannot access injectable chemo; relapsed patients First-line for dogs that can tolerate IV chemo First-line or relapsed; requires IV access

Laverdia does not appear to cause cross-resistance with other chemotherapy drugs. This means that if a dog starts on Laverdia and later switches to CHOP or another protocol, the prior Laverdia treatment has not made the cancer resistant to those other drugs. This is an important property for treatment sequencing.

Some oncologists also use Laverdia in combination with prednisone or as part of multi-drug protocols, although the label dosing and safety data are based on Laverdia as a single agent. Combination strategies should be discussed with a veterinary oncologist, as drug interactions and cumulative side effects need to be managed.

The drug has shown particularly promising signals in T-cell lymphoma, which historically responds more poorly to standard CHOP protocols than B-cell lymphoma. Having an oral option that targets a different mechanism of action is clinically significant for this subset of patients.

When Laverdia is — and is not — the right choice

Laverdia may be appropriate when:

  • The owner cannot afford or cannot practically manage multi-visit injectable chemotherapy protocols.
  • The dog has relapsed after prior chemotherapy and the owner wants to try a different mechanism of action.
  • The dog has T-cell lymphoma and the oncologist recommends trying a SINE inhibitor.
  • The dog is a reasonable candidate for oral medication and the household can comply with the chemotherapy handling precautions.

Laverdia is not a substitute for CHOP when the owner and dog can pursue the gold-standard protocol. CHOP produces higher and more durable remission rates. Laverdia is also not appropriate for households where pregnant women or young children cannot reliably avoid contact with the drug or the dog's waste.

What owners should ask their veterinarian

  • Is my dog's lymphoma B-cell or T-cell, and does that affect whether Laverdia is recommended?
  • What monitoring schedule will we follow, and what blood work is needed at each visit?
  • Can you walk me through the client information sheet on handling precautions before I take the first dose home?
  • What signs should prompt me to call between scheduled visits — specifically, how many missed meals, how much vomiting, or what level of lethargy is concerning?
  • If Laverdia stops working, what are the next treatment options, and does having used Laverdia affect their effectiveness?

Sources

Topics
Oncology
Related Articles